EGFR DEGRADERS AND METHODS OF USE
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
1 . A compound of Formula (X):
or a N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a deuterated analog thereof, wherein:
R 1 is selected from —P(O)R 1a R 1b , —SO 2 R 1a , —SO 2 —NR 1a R 1b or —N(R 1a )—SO 2 R 1b , wherein R 1a and R 1b are each independently selected from hydrogen, —C 1-8 alkyl or C 3 -C 8 cycloalkyl, said —C 1-8 alkyl or C 3 -C 8 cycloalkyl is optionally substituted with at least one halogen;
Z 5 is selected from —CR 2 , or N;
Z 6 is selected from —CR 3 , or N;
Z 7 is selected from —CR 9 , or N;
Z 8 is selected from —CR 10 , or N;
at least one of Z 5 , Z 6 , Z 7 and Z 8 is N;
R 2 and R 3 are each independently selected from hydrogen, halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, 5- to 12-membered heteroaryl, —CN, —OR 2a , —SO 2 R 2a , —SO 2 NR 2a R 2b , —COR 2a , —CO 2 R 2a , —CONR 2a R 2b , —NR 2a R 2b , —NR 2a COR 2b , —NR 2a CO 2 R 2b , or —NR 2a SO 2 R 2b , wherein each of —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 2d ; or
R 2 and R 3 together with the carbon atoms to which they are attached, form a 5-6 membered saturated or partially or completely unsaturated (preferably completely unsaturated, i.e., aromatic) ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent R 2e ;
R 2e , at each occurrence, is independently hydrogen, halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 1-8 alkoxy, —C 3 -C 8 cycloalkyl, oxo, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, 5- to 12-membered heteroaryl, —CN, —SO 2 R 2a , —SO 2 NR 2a R 2b , —COR 2a , —CO 2 R 2a , —CONR 2a R 2b , —NR 2a R 2b , —NR 2a COR 2b , —NR 2a CO 2 R 2b or —NR 2a SO 2 R 2b , wherein each of —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 1-8 alkoxy, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 2a ;
R 2a and R 2b are each independently selected from hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 1-8 alkoxy-C 1-8 alkyl-, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl;
R 2d , at each occurrence, is independently halogen, —OH, —C 1-8 alkyl, —C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl, or 5- to 12-membered heteroaryl;
R 4 is selected from hydrogen, halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 1-8 alkoxy, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl, 5- to 12-membered heteroaryl, —CN, —SO 2 R 4a , —SO 2 NR 4a R 4b , —COR 4a , —CO 2 R 4a , CONR 4a R 4b , —NR 4a R 4b , —NR 4a COR 4b , —NR 4a CO 2 R 4b , or —NR 4a SO 2 R 4b , wherein each of —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 1-8 alkoxy, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl or 5- to 12-membered heteroaryl is optionally substituted with halogen, —C 1-8 alkoxy, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, 5- to 12-membered heteroaryl, oxo, —CN, —OR 4c , —SO 2 R 4c , —SO 2 NR 4c R 4d , —COR 4c , —CO 2 R 4c , —CONR 4c R 4d , —NR 4c R 4d , —NR 4c COR 4d , —NR 4c CO 2 R 4d , or —NR 4c SO 2 R 4d ;
R 4a , R 4b , R 4c and R 4d are each independently hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl, or 5- to 12-membered heteroaryl;
R 9 , R 10 , R 11 and R 12 are each independently selected from hydrogen, halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —NR 9a R 9b , —OR 9a , oxo, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl, 5- to 12-membered heteroaryl, or —CN, wherein each of —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 9c ; or
two R 12 together with the carbon atoms to which they are attached, form a 3- to 12-membered ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent R 9c ;
R 9a and R 9b are each independently selected from hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl or 5- to 12-membered heteroaryl, wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 9d ; or
R 9c and R 9d are each independently halogen, hydroxy, —C 1-8 alkyl, —C 1-8 alkoxy, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl, 5- to 12-membered heteroaryl, —CN or NR 9aa R 9bb , wherein each of said —C 1-8 alkyl, —C 1-8 alkoxy, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl, 5- to 12-membered heteroaryl is optionally substituted with at least one hydrogen, halogen, hydroxy, —C 1-8 alkyl, —C 1-8 alkoxy, —CN, —NH 2 or oxo, and R 9aa and R 9bb are each independently hydrogen or C 1-8 alkyl;
Z 1 , Z 2 , Z 3 and Z 4 are each independently selected from —CR z , or N;
R Z , at each occurrence, is independently selected from hydrogen, halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —NR Za R Zb , —OR Za , —SR Za , C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, 5- to 12-membered heteroaryl, or CN, wherein each of —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5- to 12-membered heteroaryl is optionally substituted with at least one R Zc ;
R Za and R Zb are each independently selected from hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5- to 12-membered heteroaryl, wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R Zd ;
R Zc and R Zd are each independently halogen, hydroxy, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5- to 12-membered heteroaryl;
L is selected from a single bond, —O—, —SO 2 —, —C(O)—, —NR L1a —, —C 3 -C 8 cycloalkylene-, * L1 —O—C 1-8 alkylene-** L1 , * L1 C 1-8 alkylene-O—** L1 , * L1 —SO 2 —C 1-8 alkylene-** L1 , * L1 C 1-8 alkylene-SO 2 —** L1 , * L1 —CO—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-CO—** L1 , * L1 —NR L1a —C 1-8 alkylene-** L1 , * L1 C 1-8 alkylene-NR L1a —** L1 , * L1 —NR L1a C(O)—** L1 , * L1 —C(O)NR L1a —** L1 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-, —[O(CR L1a R L1b ) m4 ] m5 —,
wherein each of said —C 3 -C 8 cycloalkylene-, * L1 —O—C 1-8 alkylene-** L1 , * L1 C 1-8 alkylene-O—** L1 , * L1 —SO 2 —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-SO 2 —** L1 , * L1 —C 1-8 alkylene-** L1 , * L1 C 1-8 alkylene-CO—** L1 , * L1 —NR L1a —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-NR L1a —** L1 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-,
is optionally substituted with at least one R L1c ;
wherein * L1 refers to the position attached to
moiety, and ** L1 refers to the position attached to the
moiety;
R L1a and R L1b are each independently selected from hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl, wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R L1d ;
each of said R L1c and R L1d are independently halogen, hydroxy, —C 1-8 alkyl, —C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, 5- to 12-membered heteroaryl or oxo;
L 2 is selected from a single bond, —O—, —SO 2 —, —CO—, —NR L2a , —C 3 -C 8 cycloalkylene-, * L2 -O—C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-O—** L2 , * L2 -S 2 —C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-SO 2 —** L2 , * L2 -CO—C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-CO—** L2 , * L2 —NR L2a —C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-NR L2a —** L2 , * L2 —NR L2a C(O)—** L2 , * L2 -C(O)NR L2a —** L2 —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-, —[O(CR L2a R L2b ) m4 ] m5 —,
wherein each of said —C 3 -C 8 cycloalkylene-, * L2 -O—C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-O—** L2 , * L2 -SO 2 —C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-SO 2 —** L2 , * L2 -CO—C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-CO—** L2 , * L2 —NR L2a —C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-NR L2a —** L2 , C 1-8 alkenylene-, —C 2-8 alkylene-, —C 2-8 alkynylene-,
is optionally substituted with at least one substituent R L2c ;
wherein * L2 refers to the position attached to
moiety, and ** L2 refers to the position attached to the
moiety;
R L2a and R L2b are each independently selected from hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl, wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R L2d ;
each of said R L2c and R L2d are independently halogen, hydroxy, —C 1-8 alkyl, —C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, 5- to 12-membered heteroaryl or oxo;
L 3 is selected from a single bond, —O—, —SO 2 —, —CO—, —NR L3a —, —C 3 -C 8 cycloalkylene-, * L3 -O—C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-O—** L3 , * L3 —SO 2 —C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-SO 2 —** L3 , * L3 -CO—C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-CO—** L3 , * L3 —NR L3a —C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-NR L3a —** L3 , * L3 —NR L3a C(O)** L3 , * L3 -C(O)NR L3a —** L3 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-, —[O(CR L3a R L3b ) m4 ] m5 —,
wherein each of said —C 3 -C 8 cycloalkylene-, * L3 -O—C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-O—** L3 , * L3 -S 2 —C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-SO 2 —** L3 , * L3 —CO—C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-CO—** L3 , * L3 —NR L3a —C 1-8 alkylene-** L3 , * L3 —C 1-8 alkylene-NR L3a —** L3 , C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-,
is optionally substituted with at least one substituent R L3c ;
wherein * L3 refers to the position attached to
moiety, and ** L3 refers to the position attached to the
moiety;
R L3a and R L3b are each independently selected from hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl, wherein each of said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R L3d ;
each of said R L3c and R L3d are independently halogen, hydroxy, —C 1-8 alkyl, —C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl-, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, 5- to 12-membered heteroaryl or oxo;
is selected from
Ring A is selected from 3-12 membered cycloalkyl, 3-12 membered heterocyclyl, aryl, or heteroaryl;
R 13 and R 14 are independently selected from hydrogen, halogen, CN, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 1-8 alkoxy, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl; said each —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 1-8 alkoxy, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent halogen, —C 1-8 alkyl, C 1-8 alkoxy-C 1-8 alkyl-, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl;
X 1 , X 2 , X 3 , X 4 and X 8 are each independently selected from —CR a , or N;
X 5 , X 6 , X 7 and X 9 are each independently selected from —NR a —, —O—, —S— and —CR a R b —;
X 12 and X 13 are each independently selected from —NR a — and —O—;
L 4 , L 5 and L Y are each independently selected from a single bond, —O—, —NR a —, —(CR a R b ) n8 —, —O(CR a R b ) n8 —, —NR a (CR a R b ) n8 — or —C(O)—;
Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from CR a or N;
Y 5 is selected from NR a , O or S;
R a and R b are each independently selected from hydrogen (H, D or T), halogen, CN, —C 1-8 alkyl, —C 1-8 alkoxy, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl or 5- to 12-membered heteroaryl, wherein each of said —C 1-8 alkyl, —C 1-8 alkoxy, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent halogen, hydroxy, halogen, —C 1-8 alkyl, —C 1-8 alkoxy, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, —C 6 -C 12 aryl or 5- to 12-membered heteroaryl; or
R a and R b together with the carbon atoms to which they are attached, form a 3- to 12-membered ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent halogen, hydroxy, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 1-8 alkoxy, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl;
m 1 is 0 or 1;
m 2 and m 3 are each independently 0, 1, 2, 3, 4, 5, 6, 7 or 8;
m 4 and m 5 are each independently 0, 1, 2 or 3;
n, n 1 , n 2 , n 3 , n 4 and n 5 are each independently 0, 1, 2 or 3; and
n 6 is 0, 1, 2, 3 or 4
n 7 is 0, 1, 2 or 3;
n 8 is 0, 1, 2, 3, 4, 5, 6, 7 or 8.
2 . The compound of claim 1 , wherein R 1 is selected from —P(O)R 1a R 1b or —N(R 1a )—SO 2 R 1b , wherein R 1a and R 1b are each independently selected from hydrogen, —C 1-8 alkyl (preferably —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 or —C 5 H 11 ; more preferably —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , -iso-C 3 H 7 , —CH 2 CH 2 CH 2 CH 3 , -iso-C 4 H 9 , -sec-C 4 H 9 or -tert-C 4 H 9 ) or C 3 -C 8 cycloalkyl (preferably cyclopropyl, cyclobutyl or cyclopentyl).
3 . The compound of any one of claims 1 - 2 , wherein R 1 is selected from —P(O)(CH 3 ) 2 , —NH—SO 2 CH 3 or —N(CH 3 )—SO 2 CH 3 .
4 . The compound of any one of claims 1 - 3 , wherein one of Z 7 and Z 8 is N.
5 . The compound of any one of claims 1 - 4 , wherein Z 7 is N.
6 . The compound of any one of claims 1 - 5 , wherein one of Z 7 and Z 8 is N, Z 5 is —CR 2 , and Z 6 is —CR 3 .
7 . The compound of any one of claims 1 - 6 , wherein R 2 and R 3 are each independently selected from hydrogen, —F, —Cl, —Br, —I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, 5- to 12-membered heteroaryl, —CN, —OR 2a , —SO 2 R 2a , —SO 2 NR 2a R 2b , —COR 2a , —CO 2 R 2a , —CONR 2a R 2b , —NR 2a R 2b , —NR 2a COR 2b , —NR 2a CO 2 R 2b , or —NR 2a SO 2 R 2b , wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 2d ,
R 2a and R 2b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, C 1-8 alkoxy-C 1-8 alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl;
R 2d , at each occurrence, is independently halogen, —OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
8 . The compound of any one of claims 1 - 7 , wherein R 2 and R 3 are each independently selected from hydrogen, halogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl or octyl, preferable selected from —H, —F, —Cl, —Br, —I, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH 2 CH 2 CH 3 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —C(CH 3 ) 3 .
9 . The compound of any one of claims 1 - 6 , wherein when Z 5 is —CR 2 and Z 6 is —CR 3 , wherein R 2 and R 3 together with the carbon atoms to which they are attached, form a 5 or 6 membered unsaturated (preferred aromatic) ring, said ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent R 2e ;
R 2e , at each occurrence, is independently hydrogen, —F, —Cl, —Br, —I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or oxo, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent R 2d ;
R 2d , at each occurrence, is independently —F, —Cl, —Br, —I, —OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or phenyl.
10 . The compound of any one of claims 1 - 9 , wherein the
moiety is
wherein R 2 , R 3 , Z 7 , Z 8 , R 1a and R 1b are defined as in claim 1 .
11 . The compound of claim 10 , wherein the
moiety is
wherein Cy1 is a 5-6 membered unsaturated (preferred aromatic) or saturated ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;
preferable, the
moiety is
wherein R 2e , Z 7 , Z 8 , R 1a and R 1b are defined as in claim 1 .
12 . The compound any of claim 1 - 11 , wherein R 2e at each occurrence, is independently hydrogen, —F, —Cl, —Br, —I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or oxo, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent R 2d ;
R 2d , at each occurrence, is independently —F, —Cl, —Br, —I, —OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or phenyl.
13 . The compound any one of claim 1 - 12 , wherein R 2e at each occurrence, is independently hydrogen, —F, —Cl, —Br, —I, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH 2 CH 2 CH 3 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CF 3 ,
14 . The compound of one of claim 1 - 13 , wherein the
moiety is
15 . The compound of any one of claims 1 - 14 , wherein R 9 , R 10 , R 11 and R 12 are each independently selected from hydrogen, —F, —Cl, —Br, —I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, —NH 2 or oxo, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl is optionally substituted with at least one substituent R 9c ; or
two R 12 together with the carbon atoms to which they are attached, form a 3, 4, 5, 6, 7 or 8-membered ring, said ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent R 9c ;
R 9c is independently —F, —Cl, —Br, —I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, —C 2-8 alkenyl, —C 2-8 alkynyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, NH 2 , or —NHCH 3 .
16 . The compound of any one of claims 1 - 15 , wherein R 9 , R 10 , R 11 and R 12 are each independently selected from hydrogen, F, Cl, Br, —NH 2 , —CH 3 , —C 2 H 5 , —C 3 H 7 , —CH 2 F, —CHF 2 , —CF 3 , —C 4 H 9 , —C 5 H 11 , —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , —CN, cyclopropyl or oxo; or
two R 12 together with the carbon atoms to which they are attached, form a 3, 4, 5, 6, 7 or 8-membered ring, said ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent —H, —F, —Cl, —Br, —I, methyl, ethyl, propyl, butyl, —NH 2 , —NHCH 3 , —OH, —OCH 3 , —OC 2 H 5 , cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
17 . The compound of any one of claims 1 - 16 , wherein R 4 is selected from —H, —F, —Cl, —Br, —I, —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl or —CN, wherein each of —CH 3 , —C 2 H 5 , —C 3 H 7 , —C 4 H 9 , —C 5 H 11 , —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OC 4 H 9 , —OC 5 H 11 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or phenyl is optionally substituted with —F, —Cl, —Br, —I, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, 5- to 12-membered heteroaryl, oxo, —CN, —OR 4c , —SO 2 R 4c , —SO 2 NR 4c R 4d , —COR 4c , —CO 2 R 4c , —CONR 4c R 4d , —NR 4c R 4d , —NR 4c COR 4d , —NR 4c CO 2 R 4d , or —NR 4c SO 2 R 4d ;
R 4c and R 4d are each independently hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5- to 12-membered heteroaryl.
18 . The compound of any one of claims 1 - 17 , wherein R 4 is selected from —F, —Cl, —Br, —I, —CH 3 , —CF 3 , —CH 2 F, or —CHF 2 .
19 . The compound of any one of claims 1 - 18 , wherein L is selected from a single bond, —O—, —SO 2 —, —C(O)—, —NR L1a —, —C 3 -C 8 cycloalkylene-, * L1 —O—C 1-8 alkylene-** L1 , * L1 C 1-8 alkylene-O—** L1 , * L1 —SO 2 —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-SO 2 —** L1 , * L1 —CO—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-CO—** L1 , * L1 —NR L1a —C 1-8 alkylene-** L1 , * L1 C 1-8 alkylene-NR L1a —** L1 , * L1 —NR L1a C(O)—** L1 , * L1 —C(O)NR L2a —** L1 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-, —[O(CR L1a R L1b ) m4 ] m5 —,
wherein each of said —C 3 -C 8 cycloalkylene-, * L1 —O—C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-O—** L1 , * L1 —SO 2 —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-SO 2 —** L1 , * L1 —CO—C 1-8 alkylene-** L1 , * L1 C 1-8 alkylene-CO—** L1 , * L1 —NR L1a —C 1-8 alkylene-** L1 , * L1 —C 1-8 alkylene-NR L1a —** L1 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-,
is optionally substituted with at least one R L1c ;
R L1a and R L1b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxazolidinyl, imidazolidinyl, thiazolidinyl, pyrazolidinyl, morpholinyl, piperidinyl, piperazinyl, oxazinyl, imidazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, triazolyl, thiophenyl, furanyl, pyridyl, pyrimidinyl or pyrazinyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxazolidinyl, imidazolidinyl, thiazolidinyl, pyrazolidinyl, morpholinyl, piperidinyl, piperazinyl, oxazinyl, imidazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, triazolyl, thiophenyl, furanyl, pyridyl, pyrimidinyl or pyrazinyl is optionally substituted with at least one substituent R L1d ;
each of said R L1c and R L1d are independently —F, —Cl, —Br, —I, —OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxazolidinyl, imidazolidinyl, thiazolidinyl, pyrazolidinyl, morpholinyl, piperidinyl, piperazinyl, oxazinyl, imidazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, triazolyl, thiophenyl, furanyl, pyridyl, pyrimidinyl, pyrazinyl or oxo;
20 . The compound of any one of claims 1 - 19 , wherein L 1 is selected from a single bond, —C 1-8 alkylene-(preferably —CH 2 —, —C 2 H 4 —, —C 3 H 6 —), —CO—, —O—, —N(CH 3 )—, —NH—,
21 . The compound of any one of claims 1 - 20 , wherein X 1 and X 2 are each independently selected from —CR a or N;
R a is selected from hydrogen, —F, —Cl, —Br, —I, CN, methyl, ethyl, methoxy, ethoxy, or cyclopropyl, wherein each of said methyl, ethyl, methoxy, ethoxy, or cyclopropyl is optionally substituted with at least one substituent —F, —Cl, —Br, —I, hydroxy, methyl, ethyl, (preferably, X 1 and X 2 are each independently selected from CH, C(F), C(CH 3 ) or N);
m1=1 or 0;
R 12 is hydrogen, oxo, methoxymethyl, hydroxymethyl, —CN or —CH 3 .
22 . The compound of any one of claims 1 - 21 , wherein m1 is 1; preferably,
moiety is
wherein * X refers to the position attached to
moiety, and ** X refers to the position attached to the
moiety.
23 . The compound of any one of claims 1 - 21 , wherein m1 is 0.
24 . The compound of any one of claims 1 - 23 , wherein
moiety is
25 . The compound of any one of claims 1 - 24 , wherein m2 is selected from 0, 1, 2, 3, 4 or 5.
26 . The compound of any one of claims 1 - 25 , wherein L 2 is selected from a single bond, —O—, —SO 2 —, —CO—, —NR L2a —, —C 3 -C 8 cycloalkylene-, * L2 —O—C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-O—** L2 , * L2 -SO 2 —C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-SO 2 —** L2 , * L2 -CO—C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-CO—** L2 , * L2 —NR L2a —C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-NR L2a —** L2 , * L2 —NR L2a C(O)—** L2 , * L2 —C(O)NR L2a —** L2 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-, —[O(CR L2a R L2b ) m4 ] m5 —,
wherein each of said —C 3 -C 8 cycloalkylene-, * L2 -C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-O—** L2 , * L2 -SO 2 C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-SO 2 —** L2 , * L2 -CO—C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-CO—** L2 , * L2 —NR L2a —C 1-8 alkylene-** L2 , * L2 -C 1-8 alkylene-NR L2a —** L2 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-,
is optionally substituted with at least one substituent R L2c ;
R L2a and R L2b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxazolidinyl, imidazolidinyl, thiazolidinyl, pyrazolidinyl, morpholinyl, piperidinyl, piperazinyl, oxazinyl, imidazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, triazolyl, thiophenyl, furanyl, pyridyl, pyrimidinyl or pyrazinyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxazolidinyl, imidazolidinyl, thiazolidinyl, pyrazolidinyl, morpholinyl, piperidinyl, piperazinyl, oxazinyl, imidazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, triazolyl, thiophenyl, furanyl, pyridyl, pyrimidinyl or pyrazinyl is optionally substituted with at least one substituent R L2d ;
each of said R L2c and R L2d are independently —F, —Cl, —Br, —I, —OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxazolidinyl, imidazolidinyl, thiazolidinyl, pyrazolidinyl, morpholinyl, piperidinyl, piperazinyl, oxazinyl, imidazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, triazolyl, thiophenyl, furanyl, pyridyl, pyrimidinyl, pyrazinyl or oxo;
27 . The compound of any one of claims 1 - 26 , wherein L 2 is selected from a single bond, —C 1-8 alkylene-(preferably —CH 2 —, —C 2 H 4 —, —C 3 H 6 —), —CO—, —O—, —N(CH 3 )—, —NH—,
28 . The compound of any one of claims 1 - 27 , wherein m3 is 0, 1, 2, 3, 4, 5 or 6.
29 . The compound of any one of claims 1 - 28 , wherein L 3 is selected from a single bond, —O—, —SO 2 —, —CO—, —NR L3a —, —C 3 -C 8 cycloalkylene-, * L3 —O—C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-O—** L3 , * L3 —SO 2 —C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-SO 2 —** L3 , * L3 -CO—C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-CO—** L3 , * L3 —NR L3a —C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-NR L3a —** L3 , * L3 —NR L3a C(O)** L3 , * L3 —C(O)NR L3a a** L3 , —C 1-8 alkylene-, —C 2-8 alkenylene-, —C 2-8 alkynylene-, —[O(CR L3a R L3b ) m4 ] m5 —,
wherein each of said —C 3 -C 8 cycloalkylene-, * L3 -O—C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-O—** L3 , * L3 -SO 2 —C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-SO 2 —** L3 , * L3 -CO 1-8 alkylene-CO—** L3 , * L3 —NR L3a —C 1-8 alkylene-** L3 , * L3 -C 1-8 alkylene-NR L3a —** L3 , —C 1-8 alkylene-, C 2-8 alkenylene-, —C 2-8 alkynylene-,
is optionally substituted with at least one substituent R L3c ;
R L3a and R L3b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxazolidinyl, imidazolidinyl, thiazolidinyl, pyrazolidinyl, morpholinyl, piperidinyl, piperazinyl, oxazinyl, imidazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, triazolyl, thiophenyl, furanyl, pyridyl, pyrimidinyl or pyrazinyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxazolidinyl, imidazolidinyl, thiazolidinyl, pyrazolidinyl, morpholinyl, piperidinyl, piperazinyl, oxazinyl, imidazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, triazolyl, thiophenyl, furanyl, pyridyl, pyrimidinyl or pyrazinyl is optionally substituted with at least one substituent R L3d ;
each of said R L3c and R L3d are independently —F, —Cl, —Br, —I, —OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxazolidinyl, imidazolidinyl, thiazolidinyl, pyrazolidinyl, morpholinyl, piperidinyl, piperazinyl, oxazinyl, imidazolyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, triazolyl, thiophenyl, furanyl, pyridyl, pyrimidinyl, pyrazinyl or oxo.
30 . The compound of any one of claims 1 - 29 , wherein L 3 is selected from single bond, —C 1-8 alkylene-(preferably —CH 2 —, —C 2 H 4 —, —C 3 H 6 —), —CO—, —O—, —N(CH 3 )—, —NH—,
31 . The compound of any one of claims 1 - 30 , wherein
is selected from —CH 2 CH 2 —,
wherein * refers to the position attached to
moiety, and ** refers to the position attached to the
moiety.
32 . The compound of any one of claims 1 - 31 , wherein is selected from
Ring A is selected from 5- to 7-membered cycloalkyl, 5- to 7-membered heterocyclyl, aryl, or heteroaryl;
R 14 is independently selected from hydrogen, halogen, —C 1-8 alkyl, —C 1-8 alkoxy, or CN; said each —C 1-8 alkyl, or —C 1-8 alkoxy is optionally substituted by one or more halogen or —C 1-8 alkyl; preferably R 14 is independently selected from H, F, Cl, Br, I, CH 3 , —OCH 3 , CH 2 F, CN, CHF 2 , or CF 3 ;
X 8 is independently selected from CH, CD, C(CH 3 ), C(C 2 H 5 ), C(C 3 H 7 ), C(CN) or N;
L 4 is independently selected from a single bond,
—O—, —NH—, —CH 2 —, —CHF—, or —CF 2 —;
Y 1 , Y 2 , and Y 3 are each independently selected from CR a or N;
X 9 is CH 2 ;
R a is each independently selected from hydrogen, halogen, —C 1-8 alkyl, or —C 1-8 alkoxy, wherein each of said —C 1-8 alkyl or —C 1-8 alkoxy is optionally substituted with at least one or more halogen, hydroxy, halogen, —C 1-8 alkyl, or —C 1-8 alkoxy; and
n6 is independently 0, 1 or 2.
33 . The compound of any one of claims 1 - 32 , wherein is
Wherein L 5 and L 6 is independently selected from a single bond,
—O—, —NH—, —NMe-, —N(CH 2 CH 3 )—, —CH 2 —, —CHF—, —CF 2 —, —C(CH 3 ) 2 — or —CO— (preferably L 5 is —CO— or —CH 2 —, and L 6 is
—O—, —NH—, —NMe-, —N(CH 2 CH 3 )—, —CH 2 —, —CHF—, —CF 2 —, —C(CH 3 ) 2 — or —CO—);
X 9 is CH 2 ;
each R 13 is independently selected from hydrogen, —F, —Cl, —Br, —I, CN, —C 1-8 alkyl, or —C 1-8 alkoxy;
n 6 is 0 or 1; and
n 7 is 0, 1 2.
34 . The compound of any one of claims 1 - 33 , wherein is
Wherein L 4 is independently selected from a single bond,
—O—, —NH—, —CH 2 —, —CHF—, or —CF 2 —;
X 8 is independently selected from CH, CD, C(CH 3 ), C(C 2 H 5 ), C(C 3 H 7 ), C(F) or N;
X 9 is CH 2 ;
each R 13 is independently selected from hydrogen, —F, —Cl, —Br, —I, —CN, —C 1-8 alkyl, or —C 1-8 alkoxy;
Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from CH, C(CH 3 ), C(CH 2 CH 3 ), C(F), or N;
Y 5 is selected from NH, N(CH 3 ), O or S;
n 6 is 0 or 1; and
n 7 is 0, 1 or 2
35 . The compound of any one of claims 1 - 34 , wherein is selected from
36 . The compound of any one of claims 1 - 35 , wherein Z 1 , Z 2 , Z 3 and Z 4 are each independently —CR Z ;
R Z , at each occurrence, is independently selected from hydrogen, —F, —Cl, —Br, —I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, —NR Za R Zb , —OR Za , —SR Za , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, or CN, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one R Zc ;
R Za and R Zb are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl, wherein each of said hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R Zd ;
R Zc and R Zd are each independently —F, —Cl, —Br, —I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, —C 1-8 alkoxy, —C 2-8 alkenyl, —C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
37 . The compound of any one of claims 1 - 36 , wherein R Z is independently selected from H, —CH 3 , —C 2 H 5 , F, —CH 2 F, —CHF 2 , —CF 3 , —OCH 3 , —OC 2 H 5 , —C 3 H 7 , —OCH 2 F, —OCHF 2 , —OCH 2 CF 3 , —OCF 3 , —SCF 3 , —CF 3 or —CH(OH)CH 3 .
38 . The compound of any one of claims 1 - 37 , wherein the deuterium substitution is on the Degron moiety, preferable, deuterium substitution is on X 8 .
39 . The compound of any one of claims 1 - 38 , wherein the compound is selected from
40 . A pharmaceutical composition comprising a compound of any one of claims 1 - 39 or a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof, together with a pharmaceutically acceptable excipient.
41 . A method of decreasing EGFR activity by inhibition and/or degradation, which comprises administering to an individual the compound according to any one of claims 1 - 39 , or a pharmaceutically acceptable salt thereof, including the compound of formula (I) or the specific compounds exemplified herein.
42 . The method of claim 41 , wherein the disease is selected from cancer, preferred pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, or non-small cell lung cancer.
43 . Use of a compound of any one of claims 1 - 39 or a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof in the preparation of a medicament for treating a disease that can be affected by EGFR modulation.
44 . The use of claim 43 , wherein the disease is cancer, preferred pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, or non-small cell lung cancer.
45 . A method of treating a disease or disorder in a patient comprising administering to the patient a therapeutically effective amount of the compound any one of claims 1 - 39 , or a pharmaceutically acceptable salt thereof as a EGFR kinase inhibitor and/or degrader, wherein the disease or disorder is associated with inhibition of EGFR.
46 . The method of claim 45 , wherein the disease is selected from cancer, preferred pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, or non-small cell lung cancer.